In the News

May 30, 2017

bioSyntagma Core Patent for Cancer Research Awarded by USPTO

Phoenix, AZ — bioSyntagma, LLC announced today that the United States Patent and Trademark Office fully issued patent # 15/099,121 for “Method and Apparatus for Extracting and Collecting Single Cells from Formalin-Fixed Paraffin Embedded Tissues,” which bioSyntagma has exclusively licensed from Arizona Technology Enterprises (AzTE). This patent is the foundational technology for the company’s unique […]

Read More

January 6, 2017

bioSyntagma Awarded Competitive Grant from National Science Foundation: Small Business Innovation Research Program Provides Seed Funding for R&D into Tissue Heterogeneity

January 6, 2017 Phoenix, AZ — bioSyntagma, LLC, a developer of life science tools for single and multi-cell analysis announced today it has been has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant of $213,904 to conduct basic research and development, (R&D).  The aims of this grant are to further […]

Read More

September 20, 2016

bioSyntagma to Present Poster at 2016 Advances in Genome Biology and Technology Personalized Health Conference

September 20th, 2016 bioSyntagma Developing New Microfluidic Tool for Processing Formalin Fixed Paraffin Embedded (FFPE) and Frozen Tissue Specimens for in-situ Genomics Applications, to Present Poster # 207 “Novel ‘Tiling’ Method for Heterogeneity Detection in FFPE samples” at 2016 Advances in Genome Biology and Technology Personalized Health Conference Scottsdale, AZ — bioSyntagma, LLC., a developer of […]

Read More

About this project

Join us in making cancer research faster and more informative. bioSyntagma has developed a device that enables researchers and drug developers to get closer to making personalized medicine a reality by studying drug resistance in cancer patients.